ProShare Advisors
OTLK icon

ProShare Advisors’s Outlook Therapeutics OTLK Stock Holding History

ProShare Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,302
Closed -$10.3K – 2019
2023
Q4 		$10.3K Buy
1,302
+294
+29% +$2.49K ﹤0.01% 1942
2023
Q3 		$4.45K Sell
1,008
-1
-0.1% -$22 ﹤0.01% 1814
2023
Q2 		$35.1K Buy
1,009
+99
+11% +$2.7K ﹤0.01% 1801
2023
Q1 		$19.8K Buy
910
+148
+19% +$3.31K ﹤0.01% 1737
2022
Q4 		$16.5K Buy
762
+109
+17% +$2.37K ﹤0.01% 1814
2022
Q3 		$16K Sell
653
-12
-2% -$279 ﹤0.01% 1721
2022
Q2 		$13K Sell
665
-403
-38% -$11.6K ﹤0.01% 1782
2022
Q1 		$38K Buy
1,068
+95
+10% +$2.97K ﹤0.01% 2131
2021
Q4 		$26K Buy
973
+402
+70% +$14.3K ﹤0.01% 2321
2021
Q3 		$25K Sell
571
-565
-50% -$27.3K ﹤0.01% 1995
2021
Q2 		$57K Buy
+1,136
New +$52.7K ﹤0.01% 2350

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

ProShare Advisors's OTLK Position: Q1 2024 in Review

ProShare Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 1,302 shares — an estimated $10.3K sold.

ProShare Advisors first reported a position in OTLK in Q2 2021 and held it in 11 quarters. The position peaked at $57K in Q2 2021. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • ProShare Advisors reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • ProShare Advisors sold 1,302 Outlook Therapeutics shares in Q1 2024, an estimated $10.3K.
  • ProShare Advisors first reported a position in Outlook Therapeutics in Q2 2021 and held it in 11 quarters.
  • ProShare Advisors's Outlook Therapeutics position peaked at $57K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on ProShare Advisors's 13F filing for Q1 2024, filed 8 May 2024.